دورية أكاديمية
The role of axicabtagene ciloleucel as a treatment option for patients with follicular/marginal zone lymphoma
| العنوان: | The role of axicabtagene ciloleucel as a treatment option for patients with follicular/marginal zone lymphoma |
|---|---|
| المؤلفون: | Jose Sandoval-Sus, Julio C. Chavez |
| المصدر: | Therapeutic Advances in Hematology, Vol 12 (2021) |
| بيانات النشر: | SAGE Publishing, 2021. |
| سنة النشر: | 2021 |
| المجموعة: | LCC:Diseases of the blood and blood-forming organs |
| مصطلحات موضوعية: | Diseases of the blood and blood-forming organs, RC633-647.5 |
| الوصف: | Chimeric antigen receptor (CAR) T-cell therapy with axicabtagene ciloleucel (axi-cel) continues to make its way in the treatment of B-cell lymphomas. Follicular lymphoma (FL) is the second most common non-Hodgkin’s lymphoma. While its prognosis is usually good, the disease is considered incurable and patients still relapse. High-risk subgroups such as high FLIPI score or early relapses (POD24) face poor outcomes. Current treatment options with phosphatidylinositol 3-kinase (Pi3K) inhibitors or other novel agents have clinical activity but short remission with cures remaining elusive. The ZUMA-5 study of axi-cel has shown high response rates with durable remissions with manageable toxicities, particularly in poor risk FL, replicating the outcomes in smaller and earlier studies. Long-term follow up will demonstrate the real impact of axi-cel in relapsed FL. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 2040-6215 20406207 |
| العلاقة: | https://doaj.org/toc/2040-6215Test |
| DOI: | 10.1177/20406207211017788 |
| الوصول الحر: | https://doaj.org/article/8e32df6beaaf42c2b44810a460720daeTest |
| رقم الانضمام: | edsdoj.8e32df6beaaf42c2b44810a460720dae |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 20406215 20406207 |
|---|---|
| DOI: | 10.1177/20406207211017788 |